Amyloidosis: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination
With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone
in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Research Question:
Is daratumumab when given with three other drugs [cyclophosphamide, bortezomib (VELCADE®)
and dexamethasone] useful for treating patients with Amyloid light chain Amyloidosis
(also known as AL Amyloidosis)?
Basic Study Information
Purpose:
There are two treatment groups in this study. The study medication will be given in
treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib
(VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophosphamide,
bortezomib (VELCADE®) and dexamethasone (CyBorD)
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03201965?term=AMY3001&rank=1
Study Reference #: IMMY17131
Lead Researcher (Principal Investigator)
Lead Researcher: Frank Passero
Study Contact Information
Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Amyloidosis
Trial Not Found
The study you are looking for is not active at this time.
Return to Search